La Comisión Europea ha aprobado el fármaco 'JEMPERLI' (dostarlimab), de GSK, en combinación con la quimioterapia estándar ...
Esta ampliación de dostarlimab, de GSK, incluye los tumores MMRp/MSS, que representan aproximadamente el 75% de los casos de ...
Redacción MSD presenta resultados positivos de un anticuerpo en investigación para virus respiratorio sincitial Merck Sharp & ...
GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.
GSK (GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer. Read more here.
Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...
GSK’s Jemperli (dostarlimab) has been granted expanded approval by the European Commission (EC) to treat a broader range of endometrial cancer patients. The PD-1-blocking antibody has been authorised ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback